Acute Hyperkinetic Movement Disorders as a Multifactorial Pharmacodynamic Drug Interaction Between Methylphenidate and Risperidone in Children and Adolescents - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35489029/
As outlined in changes to the US prescribing information for all methylphenidate and risperidone products, health care professionals should be aware that changes to this combination may be associated with a pharmacodynamic drug-drug interaction resulting in acute hyperkinetic movement disorder.
Implications/conclusions: As outlined in changes to the US prescribing information for all methylphenidate and risperidone products, health care professionals should be aware that changes to this combination may be associated with a pharmacodynamic drug-drug interaction resulting in acute hyperkinetic movement disorder.
• Source: Journal of Clinical Psychopharmacology
• Implications/Conclusions: “As outlined in changes to the US prescribing information for all methylphenidate and risperidone products, health care professionals should be aware that changes to this combination may be associated with a pharmacodynamic drug-drug interaction resulting in acute hyperkinetic movement disorder.”
• Investigators assessed postmarketing reports of suspected acute hyperkinetic movement disorders tied to the administration of ADHD stimulants and antipsychotics.
• The authors found 36 cases of acute hyperkinetic movement disorder linked to the use of ADHD stimulants-antipsychotics. Methylphenidate products were the most common offenders followed by amphetamine products and atomoxetine.
• With regard to antipsychotics, all 36 cases involved second-generation drugs—especially risperidone.
• Most cases involved boys between 6 and 12 years, with 53% occurring within 24 hour of the drug change. Acute dystonic reactions were the most frequent movement disorder reported.